PowerPoint Presentation


Annual General Meeting


Dr James Campbell, CEO 11 November 2015


ASX: PAB


This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Patrys Limited to be materially different from the statements in this presentation.


Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of the Company's patent protection.


  1. Annual General Meeting

    November 2015


    Challenges


    • PAT-SM6 manufacturing difficulties


      o Clinical trial deferral


    • CAR T cell program discontinued


      Developments


    • Board of Directors unified in its commitment to rebuilding shareholder value


    • Appointed experienced CEO


    • Completed Chinese licensing deal for clinical candidate PAT-SC1


    • Completed corporate restructuring - strong cash position


    • Completing transformation


  2. Annual General Meeting

    November 2015



    John Read

    James Campbell Mike Stork

    Suzy Jones Melanie Leydin Deanne Greenwood

    Valentina Dubljevic

    Chairman

    CEO & Managing Director Non-Executive Director Non-Executive Director CFO & Company Secretary

    VP, Business Development & IP

    VP, Scientific & Clinical Development


    • International clinical and business development expertise

    • Substantial expertise in antibody development

    • Experienced in corporate financings, licensing and M&A transactions

    • Extensive big biotech & pharma contacts



  3. Annual General Meeting


November 2015

distributed by